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We thank Meijers and Evenepoel1 for their comments in
‘Targeting hyperphosphatemia: truth or dare.’ We agree
that the most desirable study of phosphorus binders on
dialysis is a blinded, placebo-controlled randomized trial.
We also agree that challenging existing paradigms is
essential, especially when those paradigms themselves are
based largely on expert opinion, as in the case for serum
phosphate targets on dialysis. Unfortunately, however,
practical considerations must often prevail over ideal
theory to force compromises in the interest of progress.
In our opinion, the use of phosphorus binders on dialysis
is one example where such concessions may need to be
made. We would eagerly support and participate in a
double-blinded placebo-controlled study if it was proven
that recruitment and retention of participants was feasible
in the real world. We are skeptical, however, given the
widespread view among nephrologists that control of
phosphate is the most important aspect of the manage-
ment of mineral metabolism on dialysis. This attitude
would lead to preferential withdrawal of participants from
the placebo arm in the event of severe hyperphosphatemia.
With limited research resources and numerous questions
to be answered, the risk of failure of the ‘perfect’
phosphorus binder study on dialysis due to poor enroll-
ment, limited power, and bias would be unacceptably high.
At the crossroads of theory and practice, we believe that a
trial of more- versus less-intensive phosphate control will
present a far greater chance for operational success and
will yield critically important results that would be readily
transferable into practice. Regardless of how the nephrol-
ogy community ultimately proceeds, we are excited that
our blueprint has initiated a much-required dialogue
exemplified by the comments made by Meijers and
Evenepoel.
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To the Editor: Chevalier’s stimulating commentary1 refers to
the report that nearly 50% of children with a solitary kidney
in the setting of congenital anomalies of the kidney and
urinary tract (CAKUTs) would be receiving dialysis by
30 years of age.2
The Commentary states that the ‘fundamental differences
between the long-term outcomes of patients with congenital
solitary kidney and those of healthy adults undergoing
unilateral nephrectomy as renal transplant donors, who have
no increased risk for renal failure’ are nephron endowment
below the median, and the consequences of the compensatory
growth, such as glomerular hyperfiltration, hypertension, and
proteinuria, with the additional risks of progression, includ-
ing infection, hypoxia, and nephrotoxicity.
However, another possibility to be considered is the case
of a solitary sick kidney with genetically determined
microscopic defects such as glomerulocystic alterations,
glomerulomegalia, and small tubular ectasia belonging to
the large phenotypic spectrum of mutations in the hepato-
cyte nuclear factor-1b (HNF-1b), controlling the transcrip-
tion of genes expressed in the tubular epithelial cells,
including UMOD, Pkhd1, Pkd2, and Socs3 during kidney
development (Figure 1).3–5
A child with only one kidney and mutation in the HNF-1b
gene will have a natural story that is ineluctably irreversible and
leads to end-stage renal failure, and is therefore different from
that of other children with only one kidney or adult renal living
donors, even if they are exposed to similar risk factors.
Therefore, in the present era, looking toward biomarker
discovery and gene therapy, ‘monitoring children with
CAKUT ‘..not only..’ involves monitoring diet, y blood
pressure, etc.’,1 but also genetic evaluation including HNF-1b
gene mutation.
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In their letter regarding my editorial, ‘When is one kidney
not enough?’,1 Stratta et al.2 argue that mutations of HNF-1b
should be considered as an etiology for unilateral renal
agenesis, and that genetic screening should be included in the
evaluation of such patients. Mice heterozygous for a
mutation leading to a deficiency in another transcription
factor, Six2, also exhibit severe renal maldevelopment, with
marked renal hypoplasia and reduced nephron number.3 In
addition to HNF-1b and Six2, there are a number of genes
contributing to renal morphogenesis, some with more subtle
phenotypic expression. These include variants of the RETand
PAX2 alleles, each of which may result in renal hypoplasia.4,5
Importantly, the combination of hypomorphic RET and
PAX2 alleles has an additive effect in reducing the kidney
volume (a proxy for nephron number) in human neonates.5
Continued elucidation of the molecular control of renal
morphogenesis will reveal more genes responsible for both
congenital renal anomalies and progression of renal
insufficiency. Once the temporal expression and relative
contribution of individual genes in the developing kidney are
better understood, the relative risk for progression can be
assigned. As pointed out by Stratta et al., such genetic
screening could be added to the development of biomarkers
of progression and monitoring risk factors already identified.
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Figure 1 | The large spectrum of macroscopic and microscopic renal diseases associated with hepatocyte nuclear factor 1b (HNF-1b)
mutations. As most of the identified HNF-1b target gene products colocalize in the primary celium, the crucial organelle that has an
important role in controlling the proliferation of tubular cells, it provides the background to explain the large spectrum of different
macroscopic and microscopic overt renal diseases, including single kidney, hypoplastic kidney, microcystic hypoplastic kidney, horse-shoe
kidney, multicystic kidney, glomerulomegalia, glomerulocystic kidney, or kidney with small tubular cysts, that have been described in
patients with alterations in the HNF-1b gene.
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